Overview

RM1 Project 1 - tAN Naloxone

Status:
Not yet recruiting
Trial end date:
2027-10-01
Target enrollment:
Participant gender:
Summary
This two-visit, randomized, double-blind, sham-controlled trial, uses a novel naloxone blockade model in 136 individuals to determine whether the analgesic effects of a 30-minute transcutaneous auricular neurostimulation (tAN) intervention are mediated through a release of endogenous opioids. Analgesic effects of four various stimulation interventions will be measured (auricular vagus, auricular trigeminal, combination, or sham) while varying the type of intravenous (IV) infusion (either naloxone or saline) a participant is administered to determine whether the analgesic effects are mitigated by pharmacological opioid receptor blockade.
Phase:
Early Phase 1
Details
Lead Sponsor:
Medical University of South Carolina
Treatments:
Naloxone